June Tordoff

June Tordoff

Auto-generated profile, based on publicly available information

June Tordoff

School of Pharmacy, University of Otago, Dunedin, New Zealand

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NANagham J Ailabouni
Nagham J Ailabouni
PNPrasad S Nishtala
Prasad S Nishtala
DMDee Mangin
Dee Mangin
JTJune M Tordoff
June M Tordoff
Deprescribing is the process of reducing or discontinuing medicines that are unnecessary or deemed to be harmful. We aimed to investigate general practitioner (GP) perceived challenges to deprescribing in residential care and the possible enablers that support GPs to implement deprescribing. A qualitative study was undertaken using semi-structured, face-to-face interviews from two cities in New Zealand and a purpose-developed pilot-tested interview schedule. Interviews were recorded with permission and transcribed verbatim. Transcripts were read and re-read and themes were identified with iterative building of a coding list until all data was accounted for. Interviews continued until saturation of ideas occurred. Analysis was carried out with the assistance of a Theoretical Domains Framework (TDF) and constant comparison techniques. Several themes were identified. Challenges and enablers of deprescribing were determined based on participants’ answers. Ten GPs agreed to participate. Four themes were identified to define the issues around prescribing for older people, from the GPs’ perspectives. Theme 1, the ‘recognition of the problem’, discusses the difficulties involved with prescribing for older people. Theme 2 outlines the identified behaviour change factors relevant to the problem. Deprescribing challenges were drawn from these factors and summarised in Theme 3 under three major headings; ‘prescribing factors’, ‘social influences’ and ‘policy and processes’. Deprescribing enablers, based on the opinions and professional experience of GPs, were retrieved and summarised in Theme 4. The process of deprescribing is laced with many challenges for GPs. The uncertainty of research evidence in older people and social factors such as specialists’ and nurses’ influences were among the major challenges identified. Deprescribing enablers encompassed support for GPs’ awareness and knowledge, improvement of communication between multiple prescribers, adequate reimbursement and pharmacists being involved in the multidisciplinary team.

20 December 2013 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
EHErnieda Hatah
Ernieda Hatah
RBRhiannon Braund
Rhiannon Braund
JTJune Tordoff
June Tordoff
SDStephen B. Duffull
Stephen B. Duffull

1 November 2017 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
AYAmber Young
Amber Young
JTJune Tordoff
June Tordoff
ASAlesha Smith
Alesha Smith

26 October 2006 in Pharmacy World & Science
Verified
Journal Article
Closed access
PDF file
KGKenneth Grant
Kenneth Grant
NANoor Al-Adhami
Noor Al-Adhami
JTJune Tordoff
June Tordoff
JLJocelyn Livesey
Jocelyn Livesey
GBGil Barbezat
Gil Barbezat
DRDavid Reith
David Reith

17 June 2010 in Age and Ageing
Verified
Journal Article
Open access
PDF file
JTJune M. Tordoff
June M. Tordoff
MBMichael L. Bagge
Michael L. Bagge
Andrew GrayAndrew Gray
Andrew Gray
ACA. John Campbell
A. John Campbell
PNPauline Norris
Pauline Norris
Background: older people experience more chronic medical conditions than younger people, take more prescription medicines and are more likely to suffer from cognitive or memory problems. Older people are more susceptible to the adverse effects of medicines, which may reduce their quality of life or lead to hospitalisation or death. Objective: this study aims to identify medicine-taking practices amongst community-dwelling people aged ≥75 years in New Zealand. Methods: this study was carried out in an urban setting in Dunedin (population 120,000), New Zealand. Interviews of a random sample of people from the electoral roll using a structured questionnaire were conducted. Subjects were community-dwelling people aged ≥75 years taking one or more prescription medicines. From a random sample of 810 people extracted from the electoral roll intended to recruit 300 participants, 524 people met the study criteria and were invited to participate. People living in a rest home or hospital, not contactable by telephone, or now deceased, were excluded. Responses were analysed, medicines categorised by the Anatomical Therapeutic Chemical classification and adherence classed as high, medium and low using a modified four-item Morisky Medication Adherence Scale. Univariate and multivariate linear and logistic regression was applied to combinations of variables. Results: in total, 316 interviews were undertaken; a 61% response rate. Participants were 75–79 (35%), 80–84 (40%) and >85 years (25%); New Zealand European/European (84%), ‘New Zealanders’ (14%) or Maori (2%); and 141 (45%) lived alone. Almost half (49%) regularly saw a specialist and a third (34%) had been admitted to hospital in the past 12 months. Participants used a median of seven prescription medicines (range 1–19) and one non-prescription medicine (0–14). The majority (58%) believed medicines are effective and had systems/routines (92%) for remembering to take them. Doses tended to be missed following a change in routine, e.g. holiday. Men were more likely to report ‘trouble remembering’ than women (odds ratio = 1.86, 95% confidence interval 1.10–3.14; P = 0.020). Seventy-five percent of people had high or medium adherence scores and 25%, low scores. Common problems were reading and understanding labels (9 and 4%, respectively) and leaflets (12%, 6%), and difficulty swallowing solid dose forms (14%). Only 6% had problems paying for their medicines. Around 17% wanted to know more about their medicines, and some people were confused about their medicines following hospital discharge. Conclusion: overall, community-dwelling people aged ≥75 years in this study appeared to manage their medicines well and found them affordable. Nevertheless, there is a need to improve labelling, leaflets and education on medicines, particularly at hospital discharge.

26 February 2016 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
NAN. J. Ailabouni
N. J. Ailabouni
PNP. S. Nishtala
P. S. Nishtala
DMD. Mangin
D. Mangin
JTJ. M. Tordoff
J. M. Tordoff
Introduction The majority of older people with chronic diseases are prescribed multiple medicines resulting in polypharmacy. The extrapolation of the ‘single disease model’ represented by disease‐specific guidelines is a major driver for polypharmacy. Polypharmacy is associated with negative health outcomes. Safely reducing or discontinuing harmful medicines, commonly referred to as deprescribing, has been shown to reduce adverse health outcomes, healthcare costs and mortality. However, there are barriers to deprescribing such as time constraints, limited appropriate clinical resources and the influence of multiple prescribers. Aim To explore general practitioners’ (GPs’) opinions and awareness of deprescribing in an older multimorbid patient. Methods A qualitative study design using face‐to‐face semi‐structured interviews was implemented. GP practices were randomly selected from two cities in New Zealand. Face‐to‐face in depth interviews were carried out with participants. A hypothetical profile of a multimorbid patient was included to elicit discussions about whether medicines should be continued or discontinued. Interviews were transcribed verbatim for thematic analysis. Transcripts were read and re‐read. Themes were identified with iterative building of a coding list until all data were accounted for. Interviews continued until saturation of ideas occurred. Results Forty GPs were contacted and 10 consented to participate. Responses to each medicine in the hypothetical patient profile varied. Opinions on deprescribing preventive and symptomatic medicines varied a great deal. Conflicting opinions existed particularly around the prescription of statins, dipyridamole and bisphosphonates. Dilemmas around the appropriate clinical management of reflux disease and insomnia in older people also came to light. Conclusion Gaining an insight into GPs’ current prescribing patterns is important in designing any interventions aimed at reducing inappropriate prescribing. This study highlights the lack of clarity around deprescribing in multimorbidity. The participants’ individual responses varied considerably. Deprescribing guidelines may help to clarify evidence based medicine relating to controversial areas and could hence decrease this variation.